Evan Seigerman, BMO head of healthcare research, joins ‘Power Lunch’ to discuss Seigerman’s thoughts on Novo Nordisk, its competitor Eli Lilly and much more.
source
Sunday, March 1, 2026
Novo Nordisk is still worried about revenue growth next year despite obesity pill: BMO’s Seigerman
Leave a Reply
- Trending
- Comments
- Latest
Stay updated with DeFi Daily, your trusted source for the latest news, insights, and analysis in finance and cryptocurrency. Explore breaking news, expert analysis, market data, and educational resources to navigate the world of decentralized finance.